Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.40 |
| ▸ | PDE4A | P27815 | 7/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.40 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6026200 | 1.00 | KMT2A (0.47) | KMT2APDE4DPDE4BPDE4APDE4C | |
| SCHEMBL6026767 | 0.96 | KMT2A (0.45) | KMT2APDE4DPDE4BPDE4APDE4C | |
| SCHEMBL6021010 | 0.90 | KMT2A (0.51) | KMT2APDE4DPDE4BPDE4APDE4C | |
| SCHEMBL4768114 | 0.90 | KMT2A (0.51) | KMT2APDE4DPDE4BPDE4APDE4C | |
| SCHEMBL6020201 | 0.90 | KMT2A (0.51) | KMT2APDE4DPDE4BPDE4APDE4C | |
| SCHEMBL6021708 | 0.89 | KMT2A (0.52) | KMT2APDE4DPDE4BPDE4APDE4C | |
| SCHEMBL6026278 | 0.89 | KMT2A (0.39) | KMT2APDE4DPDE4BPDE4APDE4C | |
| SCHEMBL6027857 | 0.89 | PDE4D (0.41) | KMT2APDE4DPDE4BPDE4APDE4C | |
| SCHEMBL6026576 | 0.88 | ESR1 (0.42) | KMT2APDE4DPDE4BPDE4APDE4C | |
| SCHEMBL6027478 | 0.88 | KMT2A (0.38) | KMT2APDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664037-A1 | HALO SUBSTITUTED BENZO [B] THIOPHENES WITH PI3K INHIBITORY ACTIVITY AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-07 | — | — | EP | claimed |
| US-20050096350-A1 | Halo substituted benzo[b]thiophenes as therapeutic agents | CONNOLLY MICHAEL K (US) | 2005-05-05 | — | — | US | claimed |
| WO-2005023800-A1 | HALO SUBSTITUTED BENZO`B! THIOPHENES WITH PI3K INHIBITORY ACTIVITY AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-17 | — | — | WO | claimed |
| EP-1664037-A1 | HALO SUBSTITUTED BENZO [B] THIOPHENES WITH PI3K INHIBITORY ACTIVITY AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050096350-A1 | Halo substituted benzo[b]thiophenes as therapeutic agents | CONNOLLY MICHAEL K (US) | 2005-05-05 | — | — | US | disclosed |
| WO-2005023800-A1 | HALO SUBSTITUTED BENZO`B! THIOPHENES WITH PI3K INHIBITORY ACTIVITY AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096350-A1 | Halo substituted benzo[b]thiophenes as therapeutic agents | HCLS1, BRI3BP, BRPF1 | KMT2A 3608/4885PDE4D 4521/4885PDE4B 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.